United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

Mondaq

26 Jan 2024 0 shares 1 views

United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

Mondaq

Published 26 Jan 2024

On January 9, 2024, the PTAB issued final written decisions in IPR2022-01225 and IPR2022-01226, filed by Mylan on two Regeneron patents directed to dosing of aflibercept — U.S.

Full Article

United States: PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable - Goodwin Procter LLP

On January 16, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office issued a Final..

Mondaq 30 Jan 2024

United States: IPR And PGR Statistics For Final Written Decisions Issued In October 2023 - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

In October, the PTAB cancelled 694 (76.60%) instituted claims across 61 IPR and PGR Final Written Decisions, including decisions..

Mondaq 02 Jan 2024

United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

United States: PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid - Goodwin Procter LLP

You might like

Related news coverage

United States: PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable - Goodwin Procter LLP

United States: IPR And PGR Statistics For Final Written Decisions Issued In October 2023 - Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Advertisement